Clinical Trial Update: Efficacy and Saftey Study of 99mTc-ECDG in the Evaluation of Coronary Artery Disease (CAD) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the efficacy and safety of the radiopharmaceutical 99mTc-ECDG for Coronary Artery Disease, with recruitment not yet started.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• 99mTc-ECDG (Technetium-99m ECDG)

Snippet

Sponsor: Cell>Point LLC | Conditions: Coronary Artery Disease | Phase 2 | Status: NOT_YET_RECRUITING